Ernest Podrasky, MD
Cardiovascular Disease · Exeter, NHNPI 1376502823
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $3,148 of the $4,586 with a category attached, or 68.6%. Abbott accounts for 81.2% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2023 at $1,796 and has fallen 55.9% since, to $792 in 2025.
Across 44 payments — averaging $104.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Medtronic$458
- Abiomed$149
- Elutia, Inc.$148
- Atricure, Inc.$107
What the payments were for
- Travel & lodging$3,14869%
- Food & beverage$1,43831%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 34 | $3,725 |
| Medtronic(2 entities) | 6 | $458 |
| Abiomed | 2 | $149 |
| Elutia, Inc. | 1 | $148 |
| Atricure, Inc. | 1 | $107 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AVEIR$1,553
- Assurity Pacemaker$1,027
- ACCENT$641
- ECM Patch,Pouch$148
- Impella$144
- Avalus$130
- 3F$119
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$107
- Mosaic$105
How this compares
$4,586 in reported general payments places this provider in the 75th percentile of 112 cardiovascular disease providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 487 | $534,572 |
| VyndamaxTafamidis | 13 | $458,587 |
| XareltoRivaroxaban | 171 | $222,042 |
| EntrestoSacubitril/Valsartan | 39 | $47,338 |
| BrilintaTicagrelor | 41 | $31,662 |
| Repatha SureclickEvolocumab | 27 | $20,313 |
| FarxigaDapagliflozin Propanediol | 20 | $14,989 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 19 | $5,106 |
| Metoprolol Succinate | 308 | $4,973 |
| Atorvastatin Calcium | 270 | $2,823 |
| Ezetimibe | 59 | $2,283 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 76 | $2,167 |
| Rosuvastatin Calcium | 177 | $2,083 |
| Warfarin Sodium | 133 | $1,914 |
| Carvedilol | 173 | $1,555 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Exeter
- Michael BiancoExeter$6K
- Gregory GoodkinExeter$2K
- William BerndtExeter$1K
- Fahad GilaniManchester$418K
- Stephan HeoManchester$116K
- Robert CapodilupoManchester$85K
- Kevin KwakuLebanon$79K
- Michael YoungLebanon$53K
- Jeanney LewManchester$36K
- Daniel PipilasDover$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.